EvoGenix lists at 20 per cent premium
Thursday, 11 August, 2005
Antibody therapeutic developer EvoGenix (ASX:EGX) listed today on the Australian Stock Exchange at AUD$0.30, 20 per cent above its issue price of AUD$0.25.
Evogenix identifies and develops antibody-based drugs and the company's technology works in three ways: it humanises to reduce immune rejection of the original mouse antibody, optimises the antibody protein to increase potency, and conjugates to increase cell-killing activity of antibodies.
At the time of writing, shares were trading at $0.27.
"We're pretty happy about it all and the price seems to be looking pretty good," said EvoGenix CEO Merilyn Sleigh. "It's sitting around $0.26 - $0.27 which is really very good at the moment, given that biotech in general isn't the hot topic."
The company's IPO raised AUD$9 million through the issue of 36 million shares and closed oversubscribed.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
